Soleno Therapeutics (SLNO) Equity Average (2014 - 2026)

Soleno Therapeutics (SLNO) has 13 years of Equity Average data on file, last reported at $473.0 million in Q1 2026.

• Equity Average for Q1 2026 came in at $473.0 million, up 98.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $473.0 million (up 98.15% YoY), and the FY2025 annual result was $347.6 million, up 72.68% from the prior year.
• Equity Average held at $473.0 million in Q1 2026 per SLNO's latest filing, from $472.5 million in the prior quarter.
• Over five years, Equity Average peaked at $473.0 million in Q1 2026 and troughed at $6.5 million in Q1 2023.
• A 5-year average of $169.2 million and a median of $150.4 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2024: Equity Average plunged 70.65% in 2023, then soared 2715.42% in 2024.
• A 5-year view of Equity Average shows it stood at $12.8 million in 2022, then jumped by 607.4% to $90.4 million in 2023, then surged by 182.09% to $254.9 million in 2024, then surged by 85.35% to $472.5 million in 2025, then increased by 0.11% to $473.0 million in 2026.
• Business Quant data shows SLNO's Equity Average at $473.0 million in Q1 2026, $472.5 million in Q4 2025, and $367.5 million in Q3 2025.